A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Active, not recruiting · NCT06081829 · Registry updated 2025-12-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation | Cholangiocarcinoma Metastatic; Cholangiocarcinoma Non-resectable | Active, not recruiting | Phase 2 | 2025-12-09 | NCT06081829 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Servier | 21 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hokkaido University Hospital (JPN-006) | Sapporo | Japan | 1 |
| Kanagawa Cancer Center (JPN-003) | Yokohama | Japan | 1 |
| Kumamoto University Hospital (JPN-004) | Kumamoto | Japan | 1 |
| National Cancer Center Hospital (JPN-001) | Tokyo | Japan | 1 |
| National Cancer Center Hospital East (JPN-002) | Kashiwa | Japan | 1 |
| National Hospital Organization Shikoku Cancer Center (JPN-007) | Matsuyama | Japan | 1 |
| Osaka International Cancer Institute (JPN-005) | Osaka | Japan | 1 |